- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01253889
Sweetheart Study: Oral Glucose for Reducing Stress During Echocardiographic Assessment in Infants in the NICU
February 20, 2017 updated by: Liisa Holsti, Children's & Women's Health Centre of British Columbia
Glucose 25% and Facilitated Tucking for Reducing Procedural Stress During Neonatologist-performed Cardiac Echocardiography in Infants in the NICU
The purpose of this study is to compare the effect of a 25% glucose solution given via a soother with or without facilitated tucking with a similarly administered water placebo (control condition) on infant stress responses during and immediately after a neonatologist performed ECHO (np-ECHO).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
One hundred and four infants were randomized to one of four groups during a single np-ECHO examination, at the discretion of the medical team.
Randomization to soother and water (Control) with and without facilitated tucking or to soother and 25% glucose (Intervention) with or without facilitated tucking will be determined by generating randomly permuted sequential blocks of four and six allocation numbers.
Study Type
Interventional
Enrollment (Actual)
104
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Children's & Women's Health Centre of BC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 6 months (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Infants born between 26-42 weeks of gestational age admitted to the Neonatal Intensive Care Unit who require a np-ECHO for clinical purposes as indicated by the medical team.
Exclusion Criteria:
- Infants who have congenital anomalies, or a lethal condition in whom intensive care is not indicated;
- Infants below the gestational age of 26 completed weeks;
- Infants who have received analgesics or sedatives within 72 hours of the assessment;
- History of maternal abuse of controlled drugs and substances.
- Infants who are too unstable to receive oral medications or be exposed to a np-ECHO or who already have had an ECHO performed by a Pediatric Cardiologist within 4 hours.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Glucose with soother
Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO.
A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period.
Repeat application of solution as per study protocol.
No other non-pharmaceutical interventions for stress reduction will be applied.
During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
|
0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group).
This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
Other Names:
|
Placebo Comparator: Oral water with soother
Oral water first given two minutes before the first contact by the physician performing the np-ECHO.
A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period.
Repeat application of solution as per study protocol.
No other non-pharmaceutical interventions for stress reduction will be applied.
During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
|
0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group).
This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
|
Active Comparator: Oral glucose with soother and tucking
For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities.
The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
|
0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group).
This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
Other Names:
|
Placebo Comparator: Oral water with soother and tucking
For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities.
The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
|
0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group).
This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Behavioral Indicators of Infant Pain (BIIP) Score
Time Frame: study day 1
|
The Behavioral Indicators of Infant Pain (BIIP) is a reliable and valid scale for assessing acute procedural pain in preterm infants.
|
study day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to complete a standard ECHO
Time Frame: study day 1
|
Defined when ultrasound images have been acquired for all four cardiac views
|
study day 1
|
Total number of times solutions are given to infants (max 4 times)
Time Frame: study day 1
|
study day 1
|
|
Quality of np-ECHO images assessed by blinded cardiologists
Time Frame: study day 1
|
study day 1
|
|
Mean heart rate from baseline to end of ECHO
Time Frame: study day 1
|
study day 1
|
|
Cardiorespiratory instability
Time Frame: study day 1
|
study day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
December 2, 2010
First Submitted That Met QC Criteria
December 3, 2010
First Posted (Estimate)
December 6, 2010
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 20, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- H10-02069
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Echocardiography Assessment
-
Edwards LifesciencesCompletedCardiac Output and Preload Assessment | Lung Water AssessmentGermany, Switzerland
-
Centre Hospitalier Universitaire, AmiensRecruitingMortality | Cardiac Surgery | Echocardiography | Aortic ValveFrance
-
Mansoura UniversityCompletedCesarean Section | Cardiac Output | Anesthesia, Spinal | EchocardiographyEgypt
-
Umeå UniversityNot yet recruitingHip Fractures | Anesthesia | Hemodynamic Instability | Echocardiography | Risk Assessment
-
RWTH Aachen UniversityCompletedVentilation | Cardiac Output | Stress Echocardiography | Perfusion | Electric Impedance TomographyGermany
-
Aarhus University HospitalCompletedCardiac Surgery | Anesthesia | Hemodynamics | Echocardiography | Phenylephrine | Ultrasonography, Renal | Renal PerfusionDenmark
-
Technical University of MunichHealth Information Management, BelgiumCompletedAdults | Non-cardiac Surgery | Pre-operative AssessmentGermany
-
Centre Hospitalier Universitaire de NīmesCompletedHeart Diseases | Echocardiography | Medicine, Emergency | Technology Assessment, BiomedicalFrance
-
Patrick F Wouters, MD PhDCompletedEchocardiography, Doppler | Echocardiography, Three-Dimensional | Echocardiography, Transesophageal | Echocardiography, TransthoracicBelgium
-
Centre Hospitalier Universitaire de NīmesCompletedHeart Diseases | Echocardiography | Medicine, Emergency | Technology Assessment, BiomedicalFrance
Clinical Trials on Glucose 25% oral solution
-
IRCCS Burlo GarofoloCompleted
-
Assiut UniversityNot yet recruitingPain Management | Neonates Pain Management
-
University of UdineWageningen University and ResearchActive, not recruitingGlycemic Index | Oral Processing | Glucose Response | Insulin ResponseItaly
-
Lady Hardinge Medical CollegeCompleted
-
Kedrion S.p.A.inVentiv Health ClinicalTerminated
-
University Hospital Schleswig-HolsteinUniversity of KielRecruitingParkinson Disease | Nutritional and Metabolic Diseases | Sugar IntakeGermany
-
University Hospital, LilleCompletedDumping Syndrome | Oesophageal AtresiaFrance
-
Mead Johnson NutritionCompletedGastroenteritis AcuteThailand
-
Université de SherbrookeCanadian Diabetes AssociationCompleted
-
National Taiwan University HospitalCompleted